Imexpharm achieves net revenue of US$39.74 million in 2024H1

During the reporting period, the company capitalized on its leadership position in the manufacture and distribution of high-quality antibiotics and in the critically important ETC market.

At the same time, it continued to successfully align itself for growth against a backdrop of varying market conditions.

Financial highlights

Net revenue for the six months ending June 30, 2024 was VND1,008 billion (US$39.74 million), up 10% year-on-year.

Imexpharm’s ability to capitalize on its leadership of the rapidly expanding ETC market helped drive this growth, with the company seeing a 33% increase in H1 ETC revenue.

In Q1, the overall ETC market in Vietnam is reported to have grown by 15%.

Based on this comparison, the company expects its H1 performance to be well above market.

Although revenue derived from the OTC channel declined 4% overall, the company made significant progress in its strategy to partner with pharmacy chains, an increasingly important OTC sales route.

Revenue derived from this source grew 141% in the half year.

The PBT and EBITDA for the reporting period were VND161 billion (US$6.34 million) and VND215 billion (US$8.47 million), down 19% and 7%, respectively, year-on-year, as a result of a 27% rise in the cost of goods sold (COGS).

Both measures improved through Q2 as Imexpharm steadily increased production volume of its higher-value, EU-standard products, demonstrating its ability to flex production to match changing market demand for individual products.

The ongoing, positive momentum from this action led to Q2 PBT and EBITDA growth of 7% and 6%, respectively, quarter-on-quarter, and EBITDA margin stabilizing at 21%.

The rise in COGS was driven in part by the company’s proactive balancing of inventory levels to match conditions in the less sophisticated OTC market.

It was also impacted by the ongoing, planned depreciation of IMP4 and an increase in the price of active pharmaceutical ingredients.

These factors were partially offset by effective cost control in Selling General and Administrative Expenses (SG&A), which reduced by 6% year-on-year to VND213 billion (US$8.4 million).

Looking ahead to the second half of the year, the company anticipates further improvements in EBITDA and is confident it will achieve its overall targets for 2024.Imexpharm made a significant investment in marketing campaigns during H1, which is expected to translate into strong revenue growth in H2.

Product research and development at Imexpharm’s EU-GMP quality drug factory. Photo courtesy of Imexpharm

Business highlights

During the reporting period, Imexpharm continued to position itself for future domestic and overseas growth by making solid progress in its R&D program and strengthening processes within its operations.

In the first half of the year, the company launched 10 new SKUs with 93 on-going R&D projects in its innovation pipeline.

It also signed a strategic partnership with Genuone Sciences Inc. to facilitate the transfer of advanced drug manufacturing technology from Korea.

This partnership will further expand the company’s R&D capabilities to complex medications outside antibiotics, including treatments for diabetes and cardiovascular conditions.

To meet demand, particularly for its higher-value products, Imexpharm increased production volume at its IMP2, IMP3, and IMP4 factories while prudently adjusting production at IMP1 to balance with the conditions experienced in the OTC market.

In addition, the company developed plans to meet the strong market demand for its difficult-to-produce, high-quality injectables by expanding IMP4 as part of its overall factory development program.

This will allow the company to significantly boost IMP4 production capability within a timeframe targeted for the next 2-3 years.

In June, as part of its commitment to providing timely, transparent, and thorough information on its business and operations, Imexpharm hosted shareholders, investment funds, and securities company representatives at its IMP2 high-tech antibiotic factory.

Company representatives gave a comprehensive overview of Imexpharm’s EU-GMP capabilities, organizational structure, manufacturing processes, and operational strategy.

Shortly after the end of the reporting period, Imexpharm launched a project to upgrade and overhaul its operational systems by implementing the latest SAP S/4HANA enterprise resource planning software.

The company believes it is the first pharmaceutical company in Vietnam to use this advanced technology, which will allow it to pioneer new standards in operational efficiency and customer/partner service.

The high-tech antibiotic plant IMP2 meets EU-GMP standards of Imexpharm. Photo courtesy of Imexpharm

Plan to issue bonus shares to investors

On July 5, Imexpharm’s Board of Directors issued a resolution seeking shareholders’ opinion on the issuance of bonus shares.

This proposed issuance is a strategic move designed to support the company’s expansion plans over the next three to five years.

It is intended to both strengthen the company’s equity base and enhance its market liquidity.

Post issuance, Imexpharm would become the largest listed pharmaceutical company in terms of charter capital, reinforcing its market leadership and competitive position.

The increased number of shares in circulation is also expected to stimulate more active trading of Imexpharm’s stock.

As a result, the bonus share issuance has the potential to improve market perception of Imexpharm and enhance shareholder value.The bonus share issuance, which would be made on a 1:1 ratio, is expected to be fully implemented in the fourth quarter of 2024, after receiving approval from the General Meeting of Shareholders and the State Securities Commission.

Market outlook

The opportunity for Vietnamese pharmaceutical companies continues to grow, driven by recent government measures favoring local players.

In particular, the government published an action plan in February designed to implement Vietnam’s national strategy for the pharmaceutical industry.

The action plan expects the country’s local production capacity to meet 80% of domestic pharmaceutical demand and 70% of total market value by 2030.

In addition, the government issued four important Circulars (No. 03, 04, 05, 07) in H1 to address various challenges in the procurement and bidding process for medicines and medical supplies.

Imexpharm expects these measures will create favorable conditions and increase opportunities in the Vietnamese pharmaceutical market over the long term.

Commenting on the results, Chaerhan Chun, Non-Executive Chairman of Imexpharm’s Board of Directors, said that Imexpharm’s success will continue to be built on increasingly sophisticated production, operational, and financial foundations.

She is confident in the company’s ability to leverage its many strategic advantages to drive profitability and shareholder value in the full year and beyond.

“The bonus share issuance, if approved, will further underpin Imexpharm’s status as a market leader and strengthen its growth potential,” Chaerhan added.